Introduction

Glioblastoma multiforme (GBM) remains a significant therapeutic challenge that poses an unmet medical need. Despite advances in radiation therapy and improvements in chemotherapeutics and targeted therapies, outcomes remain poor, with a median survival of 14.6 months when current standard of care, such as concurrent chemoradiation therapy and adjuvant chemotherapy, are used (1). Although the exact origin of GBM (and other malignant brain tumors) is unknown, it is hypothesized that a fraction of tumor cells have cancer stem cell characteristics (glioma-initiating cells, GIC) and true tumorigenic potential (2, 3). Originally proposed 25 years ago (4), it is generally hypothesized that the resistance of GIC to radiation and chemotherapy is mediated by undefined factors in the microenvironment. GBM produce abundant transforming growth factor-β (TGF-β), a pleotropic cytokine that promotes effective DNA damage response. Consistent with this, radiation sensitivity, as measured by clonogenic assay of cultured murine (GL261) and human (U251, U87MG) glioma cell lines, increased by approximately 25% when treated with LY364947, a small-molecule inhibitor of TGF-β type I receptor kinase, before irradiation. Mice bearing GL261 flank tumors treated with 1D11, a pan-isofrom TGF-β neutralizing antibody, exhibited significantly increased tumor growth delay following IR. GL261 neurosphere cultures were used to evaluate GIC. LY364947 had no effect on the primary or secondary neurosphere-forming capacity. IR decreased primary neurosphere formation by 28%, but did not reduce secondary neurosphere formation. In contrast, LY364947 treatment before IR decreased primary neurosphere formation by 75% and secondary neurosphere formation by 68%. Notably, GL261 neurospheres produced 3.7-fold more TGF-β per cell compared with conventional culture, suggesting that TGF-β production by GIC promotes effective DNA damage response and self-renewal, which creates microenvironment-mediated resistance.

These data motivate the use of TGF-β inhibitors with radiation to improve therapeutic response in patients with GBM. Cancer Res; 72(16); 1–11. © 2012 AACR.

Abstract

The poor prognosis of glioblastoma (GBM) routinely treated with ionizing radiation (IR) has been attributed to the relative radiosensitivity of glioma-initiating cells (GIC). Other studies indicate that although GIC are sensitive, the response is mediated by undefined factors in the microenvironment. GBM produce abundant transforming growth factor-β (TGF-β), a pleotropic cytokine that promotes effective DNA damage response. Consistent with this, radiation sensitivity, as measured by clonogenic assay of cultured murine (GL261) and human (U251, U87MG) glioma cell lines, increased by approximately 25% when treated with LY364947, a small-molecule inhibitor of TGF-β type I receptor kinase, before irradiation. Mice bearing GL261 flank tumors treated with 1D11, a pan-isofrom TGF-β neutralizing antibody, exhibited significantly increased tumor growth delay following IR. GL261 neurosphere cultures were used to evaluate GIC. LY364947 had no effect on the primary or secondary neurosphere-forming capacity. IR decreased primary neurosphere formation by 28%, but did not reduce secondary neurosphere formation. In contrast, LY364947 treatment before IR decreased primary neurosphere formation by 75% and secondary neurosphere formation by 68%. Notably, GL261 neurospheres produced 3.7-fold more TGF-β per cell compared with conventional culture, suggesting that TGF-β production by GIC promotes effective DNA damage response and self-renewal, which creates microenvironment-mediated resistance. Consistent with this, LY364947 treatment in irradiated GL261 neurosphere-derived cells decreased DNA damage responses, H2AX and p53 phosphorylation, and induction of self-renewal signals, Notch1 and CXCR4. These data motivate the use of TGF-β inhibitors with radiation to improve therapeutic response in patients with GBM.

Molecular and Cellular Pathobiology

Resistance of Glioblastoma-Initiating Cells to Radiation Mediated by the Tumor Microenvironment Can Be Abolished by Inhibiting Transforming Growth Factor-β

Matthew E. Hardee1, Ariel E. Marciscano1, Christina M. Medina-Ramirez1, David Zagzag2, Ashwatha Narayana1, Scott M. Lonning3, and Mary Helen Barcellos-Hoff1

1Departments of Radiation Oncology and 2Pathology, New York University School of Medicine, New York, New York; and 3Genzyme Corporation, Framingham, Massachusetts

Corresponding Author: Mary Helen Barcellos-Hoff, Department of Radiation Oncology, 566 First Avenue, New York University Medical Center, New York, NY 10016. Phone: 212-263-3021; E-mail: mhbbarcellos-hoff@nyumc.org

doi: 10.1158/0008-5472.CAN-12-0546

©2012 American Association for Cancer Research.

www.aacrjournals.org
patient-derived tumor neurospheres to TGF-β increased the number of neurospheres in a dose-dependent fashion, and injection of these neurospheres into mice resulted in earlier appearance of more aggressive tumors (17). Ikushima and colleagues reported that autocrine TGF-β contributes to the tumorigenicity of the GIC population by activation of Sox4 and Sox2 (18). More recently, Seone and colleagues showed that TGF-β inhibitors affect a CD44hi/Id1hi GIC population via Id1 and Id3, which they propose controls the "master regulators" of the TGF-β–GIC gene program, including leukemia inhibitory factor (LIF), Sox2, Sox4, and CD44 (19).

Ionizing radiation (IR) induces TGF-β in vitro and in vivo in both normal and cancer cells (20–22). We have shown previously that reactive oxygen species are possibly involved in the radiation-induced activation of TGF-β (23) and the process is mediated by a conformational change in latency-associated peptide (LAP)–TGF-β complex, allowing the release of active TGF-β1 (24). Our studies and others have directly linked TGF-β to DNA damage responses and radiosensitivity (25, 26). Inhibiting TGF-β decreases radiation-induced phosphorylation of p53, chk2, H2AX, and rad17, all of which are substrates of ataxia telangectasia mutated (ATM), a kinase critical in the molecular response to IR-induced DNA double-strand breaks. ATM, a member of the phosphatidylinositol 3-kinase (PI3-kinase) family, is hypothesized to be a master controller of cell-cycle checkpoint signaling pathways that are required for cell response to DNA damage and for genome stability. Moreover, there is evidence using proteomic profiling that prolonged TGF-β treatment of cells can affect DNA damage repair such as Rad51 in a Smad-dependent manner (27). Notably, breast cancer cell lines treated with a small-molecule TGF-β type I receptor kinase inhibitor showed increased radiosensitivity as measured by clonogenic assay and decreased DNA damage responses to radiation, including nuclear foci of the histone variant H2AX, regardless of sensitivity to TGF-β growth control. A syngeneic model of triple-negative breast cancer showed increased tumor growth delay in response to single or fractionated radiation treatment with the addition of TGF-β neutralizing antibodies during radiotherapy (28).

The current study was aimed at determining the effects of TGF-β inhibition on radiation sensitivity of the GIC population. To assess the therapeutic potential of TGF-β inhibition during radiotherapy, we determined the relationship between sensitivity to TGF-β-mediated growth inhibition, GIC formation, molecular responses to radiation, and radio-sensitivity in human and murine GBM in vitro and in vivo. We determined that neurosphere cultures, compared with bulk populations, produce more TGF-β, whose inhibition significantly compromises both DNA damage response and self-renewal of GIC.

Materials and Methods

Cell culture

The murine glioma, GL261 (obtained from the National Cancer Institute-Frederick Cancer Research Tumor Repository, Frederick, MD; authenticated in 2012 by Idexx Radial) and human glioma U251 (a generous gift of Dr. Kevin Camphausen; authenticated in 2010 by Idexx Radial) cells were cultured in Dulbecco’s Modified Eagle Medium (DMEM) GlutaMAX (Gibco) supplemented with 10% FBS (Sigma-Aldrich) and 1% pyruvate (Gibco). Human glioma U87MG (obtained from the American Type Culture Collection (ATCC) in 2011) cells were cultured in Eagle’s Minimum Essential Medium (Gibco) with 10% FBS, at 37°C with 5% CO2. All cell lines were tested for Mycoplasma and were found negative (Cellshipper Mycoplasma test; Bionique).

For cell proliferation experiments, cells were cultured in 10% serum replacement medium (SRM; Knockout SR, Life Technologies, Inc.) containing either 2 ng/mL TGF-β1 (R&D Systems), 400 nmol/L small-molecule inhibitor of the TGF-β type I receptor kinase, LY364947 ([3-(pyridin-2-yl)-4-(4-quinonyl)](4)-1H-pyrazole; Lilly designation HTS466284; Calbiochem), 10 μg/mL of 1D11, a pan-isofrom, neutralizing TGF-β monoclonal antibody, or 13C4, a murine monoclonal isotype control antibody (kindly provided by Genzyme Inc.). Cells were trypsinized and counted using a Coulter counter at 24 and 48 hours post-treatment.

Mink lung cell luciferase assay

To measure secreted active and latent TGF-β in conditioned media, luciferase induction by conditioned media was measured in the mink lung epithelial cells transfected with truncated plasminogen activator inhibitor-1 promoter fused to the firefly luciferase reporter gene as previously described (29). Active TGF-β was measured directly in untreated samples, whereas total TGF-β (active and latent) was measured following heat activation at 80°C for 5 minutes (30). Unconditioned media was used as a control in all experiments, which was subtracted, and each condition was repeated in the presence of pan-specific TGF-β neutralizing antibody to confirm specificity. All experiments were carried out in triplicate, and results represent the mean measured value per 10⁶ cultured cells.

Neurosphere assay

Cells were diluted in serum-free growth medium (1,000 cells/mL) and plated in 500 μL in non–adherent 24-well plates (Corning-Costar). Cells were fed with 125 μL of serum-free growth medium every other day for 14 days. The culture medium consisted of serum-free DMEM/F12 (Invitrogen) supplemented with 10 U/mL heparin (Sigma-Aldrich), 2% B27 (Invitrogen), human recombinant fibroblast growth factor 2 (FGF-2, 20 ng/mL; Sigma-Aldrich), and epidermal growth factor (EGF, 20 ng/mL; Sigma-Aldrich). After 14 days, spheres were measured, and those >100 μm were counted as a neurosphere-forming unit. To generate secondary neurospheres, primary neurospheres were gently centrifuged, mechanically dissociated, and then incubated with trypsin at 37°C for 5 minutes. After centrifugation and washing with PBS, cells were diluted using neurosphere media to 1,000 cells/mL and plated onto non–adherent 24-well plates, as described above. Spheres were counted and measured from 6 different wells for each experiment. Data on the neurosphere number and size are the average ± SE of 3 independent experiments consisting of 3 replicates.
Clonogenic assay
To assess clonogenic survival of cells in monolayer culture, human and murine glioma cell lines were grown for 48 hours to 70% confluence, wherein cells were incubated with serum replacement media containing 400 nmol/L of LY364947 kinase inhibitor or 10 μg/mL pan-specific TGF-β-neutralizing antibody 1D11 or control antibody 13C4 for 48 hours before and 3 hours post radiation exposure. Cells were irradiated with 1 to 8 Gy using a Varian Clinac 2300 C/D linear accelerator (Varian), trypsinized 3 hours post-irradiation, and plated in triplicates at 3 dilutions into 6-well cell culture plates in serum-containing media. Colonies were allowed to grow for 10 to 12 days followed by fixation and staining with crystal violet. Colonies containing >50 cells were counted to determine percent survival and the number of colonies obtained from 3 replicates was averaged for each treatment. These mean values were corrected according to plating efficiency of respective controls to calculate cell survival for each dose level.

To assess clonogenic survival of cells in neurosphere culture, neurospheres were cultured for 14 days under the neurosphere conditions described above, then treated with 400 nmol/L of LY364947 kinase inhibitor for 48 hours before and 3 hours post irradiation (2 Gy). Cells were centrifuged, media aspirated, and plated in triplicate at 3 dilutions into 6-well cell culture plates in serum-containing media. The remainder of the assay was conducted as described above.

Western blotting
To examine the DNA damage response and TGF-β signaling, 5 × 10⁴ cells were grown in complete media for 48 hours, followed by LY364947 treatment (400 nmol/L) in 10% SRM for 24 hours. The cells were irradiated with 5 Gy and lysed after 1 hour, or treated with 500 pg/mL TGF-β and lysed after 30 minutes. Thereafter, the extracts were subjected to immunoblot analysis with one of the primary antibodies: phospho-Smad2 on serine 465/467 at 1:500 (clone 138D4, Upstate Biotechnology; Charlottesville, VA) at 1:500, rabbit monoclonal phospho-serine 465/467 Smad2 antibody at 1:100 (clone 138D4, CAT#3108, Cell Signaling), goat polyclonal CXCRI antibody (CAT# ab1670, Abcam) at 1:300, or rabbit monoclonal Notch1-antibody (CAT# ab8925, Abcam) at 1:100, overnight at 4°C, followed by washes and incubation with Alexa-488- or Alexa-594-labeled anti-mouse/anti-rabbit/anti-goat secondary antibodies (Molecular Probes) for 1 hour at room temperature. Specimens were counter-stained with 4',6-diamidino-2-phenylindole (DAPI), and washed in PBS-Tween20 0.1% before mounting with Vectashield mounting medium (Vector Labs). Specimens were imaged using a 40× objective with 0.95 numerical aperture Zeiss Plan-Apochromat objective on an Axiovert (Zeiss) equipped with epi-fluorescence. All images were acquired with a CCD Hamamatsu Photonics (Herrsching am Ammersee, Germany) monochrome camera at 1392 × 1040 pixel size, 12 bits per pixel (bpp) depth and assembled as false-color images using the Metamorph imaging platform (Molecular Devices, Inc.). Foci were enumerated as previously described (31).

Immunofluorescence
GL261, U251, and U87MG cells (2 × 10⁴) were grown in chamber slides in complete media for 48 hours, followed by LY364947 treatment (400 nmol/L) in 10% SRM for 24 hours before 2 Gy radiation. GL261-derived neurospheres, tumor cryosections or cells prepared as described above were fixed using 2% paraformaldehyde for 20 minutes at room temperature followed by permeabilization with 100% methanol for 20 minutes at −20°C. Then, specimens were blocked with the supernatant of 0.5% casein/PBS, stirred for 1 hours, incubated with mouse detective antigen (Biocare Medical) for an additional 3 h for murine glioma tumors, and incubated with a mouse monoclonal γH2AX antibody (clone JBW301, Upstate Biotechnology; Charlottesville, VA) at 1:500, rabbit monoclonal phospho-serine 465/467 Smad2 antibody at 1:100 (clone 138D4, CAT#3108, Cell Signaling), goat polyclonal CXCRI antibody (CAT# ab1670, Abcam) at 1:300, or rabbit monoclonal Notch1-antibody (CAT# ab8925, Abcam) at 1:100, overnight at 4°C, followed by washes and incubation with Alexa-488- or Alexa-594-labeled anti-mouse/anti-rabbit/anti-goat secondary antibodies (Molecular Probes) for 1 hours at room temperature. Specimens were counter-stained with 4',6-diamidino-2-phenylindole (DAPI), and washed in PBS-Tween20 0.1% before mounting with Vectashield mounting medium (Vector Labs). Specimens were imaged using a 40× objective with 0.95 numerical aperture Zeiss Plan-Apochromat objective on a Zeiss Axiosvert (Zeiss) equipped with epifluorescence. All images were acquired with a CCD Hamamatsu Photonics (Herrsching am Ammersee, Germany) monochrome camera at 1392 × 1040 pixel size, 12 bits per pixel (bpp) depth and assembled as false-color images using the Metamorph imaging platform (Molecular Devices, Inc.). Foci were enumerated as previously described (31).

In vivo tumor studies
Animal studies were conducted using protocols that had undergone institutional review and approval. Female C57BL/6 mice, age 6 to 8 weeks, obtained from Taconic were used for animal experiments. Animals were housed in a temperature-controlled animal care facility with a 12-hour light–dark cycle
and allowed chow and water ad libitum. GL261 cells (10⁶) were injected into the right flank of mice and allowed to grow. After the tumors reached an average size of 140 mm³, animals (n = 10 in each group) were randomized to receive 1D11 TGF-β neutralizing antibody or 13C4 control antibody (10 mg/kg, intraperitoneal injection). Twenty-four hours later, tumors were irradiated with a dose of 6 Gy using a Varian Clinac 2300 C/D linear accelerator fitted with a 25-mm radiosurgery conical collimator (BrainLAB AG). Superficial bolus (1.5-cm tissue equivalent material) was placed over the tumor, and a source-to-skin distance of 100 cm was set. Radiation was delivered at 600 cGy/min with 6 MV X-rays. Mice were monitored thrice weekly for signs of toxicity, and tumor volumes were measured with a caliper. Tumor volumes were calculated as length × width² × 0.52 with all measurements in millimeter. Animals were sacrificed when tumors reached 10 × 10 mm in two dimensions. Two hours before sacrifice, animals were injected with pimonidazole (60 mg/kg intraperitoneal, HPI). Tumors were harvested and portions were formalin fixed and frozen in O.C.T. (Sakura Tissue-Tek). All animal experiments were carried out in accordance with guidelines specified by New York University's institutional animal care and use committee. For analysis, each tumor was normalized to its pretreatment volume.

**Statistical analysis**

The significance of the difference between mean values was calculated by conducting a 2-way Student t test. The significance of the difference between the mean values for graded doses of radiation in clonogenic assays, neurosphere formation, and H2AX foci quantification was calculated by conducting a one-way ANOVA test with Tukey post hoc test. ANOVA with the Student Newman–Keuls Multiple Comparison posttest was used to determine significance between in vivo tumor growth delay measured by time-to-reach 3 times the pretreatment volume. A P value of <0.05 was considered significant.

**Results**

**Inhibition of TGF-β radiosensitizes glioma cells**

In serum-free conditions, glioma murine GL261 and human U251 and U87MG cell lines produced comparable amounts of active and latent TGF-β; GL261 162.3 ± 11.7 pg/mL and 477.6 ± 67.8 pg/mL; U251 123.1 ± 15.0 pg/mL and 420.5 ± 97.9 pg/mL; U87MG 82.5 ± 18.6 pg/mL and 350.5 ± 144.2 pg/mL, respectively, and showed intact TGF-β signaling through Smad phosphorylation (Fig. 1A). Murine GL261 and human U251MG cells were not responsive to growth modulation by exogenous TGF-β or blockade of endogenous TGF-β signaling by the addition of the TGF-β small-molecule inhibitor LY364947. U87MG cells were growth inhibited by addition of TGF-β by 19.7% ± 8.8% at 24 h and 55.3% ± 9.3% at 48 h, an effect that was reversed by the addition of the TGF-β small-molecule inhibitor LY364947 (data not shown).

Regardless of TGF-β-mediated growth modulation, addition of the TGF-β inhibitor LY364947 significantly increased the radiosensitivity of all 3 cell lines as measured in clonogenic assays of GL261, U251, and U87MG with (open symbols) and without (closed symbols) pretreatment with LY364947 24 hours before radiation exposure shows that TGF-β inhibition significantly radiosensitizes all 3 glioma cell lines. The DER at 10% survival is between 1.25 and 1.30. Mean ± SD values of triplicate determinations are shown. GL261, P = 0.04; U251, P = 0.03; U87MG, P = 0.03, ANOVA with Tukey post hoc test.

![Figure 1. TGF-β inhibition radiosensitizes glioma cells](image-url)
assay (Fig. 1B; GL261 $P = 0.04$, U251 $P = 0.03$, U87MG $P = 0.03$, ANOVA with Tukey post hoc test). The dose-enhancement ratio (DER) at 10% cell survival was 1.25 to 1.30, which indicates that 25% less dose was necessary to kill 90% of the cells by radiation when TGF-β signaling was blocked. In addition, LY364947 significantly decreased radiation-induced phosphorylation at serine 1981 and p53 phosphorylation at serine 15 in all 3 cell lines. Representative immunoblots of 2 to 3 replicates and bar plots of densitometry quantitation of mean ± SE are shown. B, TGF-β inhibition with LY364947 significantly decreased γH2AX foci (green) in murine GL261 and human U251 and U87 MG glioma cells. Nuclei are counterstained with DAPI (blue). Quantification of γH2AX foci shown below each panel reveal a significant reduction in the number of radiation-induced γH2AX foci with LY364947 in GL261 cells (19.2 ± 0.5 vs. 8.6 ± 0.4) U251 cells (11.1 ± 0.4 vs. 6.4 ± 0.2) and U87MG cells (10.8 ± 0.7 vs. 4.7 ± 0.6). *** $P < 0.0001$; ANOVA.}

There are 3 pharmacologic routes to blocking TGF-β: neutralizing the ligand, inhibiting expression, and truncating the signaling cascade (32). The pharmacokinetic properties of antibody and small-molecule kinase inhibitors result in considerable differences in the duration of TGF-β signal modulation. Several TGF-β-neutralizing antibodies that are in clinical development have shown safety and efficacy in fibrotic disorders (32, 33). We compared in vitro efficacy of TGF-β ligand captured using 1D11 pan-TGF-β neutralizing antibody, 1D11, produced the same level of radiosensitization as LY364947 (Fig. 3A; $P = 0.04$, ANOVA with Tukey post hoc test).
To test whether increased radiosensitivity conferred therapeutic benefit, we established flank tumors of GL261 cells in C57bl mice. A single intraperitoneal injection of 1D11 antibody (10 mg/kg) did not affect tumor growth rate of established tumors (9/C24150 mm3) compared with control–antibody-treated mice. Immunohistochemical detection of γH2AX in tumors harvested 1 h after radiation was reduced in mice treated with 1D11 (Fig. 3B). Consistent with inhibition of DNA damage recognition, the tumor growth delay of mice treated with 1D11 injected 24 h before a single 6 Gy fraction was significantly increased compared with mice receiving 13C4 control antibody. The y-axis represents tumor volume normalized to pretreatment volume. RT/13C4 versus RT/1D11, P < 0.05; RT/1D11 versus Sham/1D11, P < 0.01; ANOVA with Newman–Keuls multiple comparison posttest. D, the time-to-reach 3 times pretreatment volume was significantly increased by 1D11 treatment compared with antibody control 13C4. *, P < 0.05; **, P < 0.01, ANOVA with Newman–Keuls multiple comparison posttest.

Figure 3. Treatment with 1D11 pan-specific TGF-β neutralizing antibody radiosensitizes glioma cells in vitro and in vivo. A, inhibition of TGF-β using a pan-specific monoclonal antibody, 1D11, resulted in similar level of radiosensitization (1.22 at 10% cell survival) as seen with the use of the small-molecule inhibitor LY364947, P = 0.04, ANOVA with Tukey post hoc test. B, treatment with 1D11 neutralizing antibody resulted in decreased γH2AX immunofluorescence (green) 1 hour after 2 Gy compared with irradiated mice receiving control antibody 13C4. Nuclei are counterstained with DAPI (blue). C, a single intraperitoneal injection of 1D11 antibody 24 hours before irradiation (6 Gy) of GL261 flank tumors resulted in greater tumor growth delay compared with mice receiving 13C4 control antibody. The y-axis represents tumor volume normalized to pretreatment volume. RT/13C4 versus RT/1D11, P < 0.05; RT/1D11 versus Sham/1D11, P < 0.01; ANOVA with Newman–Keuls multiple comparison posttest. D, the time-to-reach 3 times pretreatment volume was significantly increased by 1D11 treatment compared with antibody control 13C4. *, P < 0.05; **, P < 0.01, ANOVA with Newman–Keuls multiple comparison posttest.

Radiosensitivity of GL261 neurosphere formation

Tumor regrowth is hypothesized to be, in large part, due to the relative response of GIC (5); therefore, we next examined the effect of TGF-β on GL261 neurosphere-forming capacity as a surrogate of GIC. Addition of LY364947 to GL261 neurosphere cultures did not affect either primary or secondary neurosphere-forming capacity. Irradiation (2 Gy) of monolayer GL261 cells significantly decreased primary neurosphere-forming capacity by 28% (P < 0.001; ANOVA). Addition of TGF-β inhibitor LY364947 decreased primary neurosphere formation by another 47% for a total reduction of 75% (Fig. 4A; P < 0.001; ANOVA). Surprisingly, irradiation of primary neurospheres did not affect secondary neurosphere formation. However, LY364947-treated, irradiated primary neurosphere cultures showed significantly decreased secondary neurosphere-forming capacity, leading to a 68% reduction (Fig. 4B; P < 0.001; ANOVA).

Given that secondary neurosphere formation, a measure of GIC self-renewal, was resistant to radiation but the majority of cells in a neurosphere are not GIC, we explored whether both populations were afforded the same degree of resistance by measuring clonogenic survival of GL261 cells dissociated from treated neurospheres. Consistent with monolayer cultures, radiation decreased colony-forming efficiency, and addition of TGF-β inhibitor LY364947 further increased the radiosensitivity of these cells by a similar magnitude to the effect seen in GL261 bulk culture. Irradiation (2 Gy) reduced the surviving fraction by 43% and the addition of LY354947 further reduced clonogenic survival by an additional 20% (Fig. 4C). Thus, non-
GICs were not afforded protection from IR in neurosphere culture. These data support the contention that GIC are specifically protected from radiation (8); however, this is conditional, that is, specific to neurosphere culture. TGF-β inhibition reduces DNA damage response in GL261 neurospheres and radiosensitizes the GIC population. We hypothesized that lack of radiation effect on secondary neurosphere formation, which is indicative of self-renewal, would be reflected in the DNA damage response. To test this hypothesis, γH2AX foci induced by 2 Gy were measured at 30 minutes post-radiation in GL261 neurospheres (Fig. 5A). Surprisingly, we observed that the number of foci per cell was 6 in neurosphere-derived cells versus 19 in monolayer culture at the same time after the same dose. The difference between monolayer and neurosphere culture could be a failure to recognize damage, a more effective DNA damage response, or both (34). Nonetheless, addition of TGF-β inhibitor LY364947 in neurosphere culture reduced radiation-induced γH2AX foci by 5.2-fold (6.2 foci/nucleus compared with 1.2 foci/nucleus; Fig. 5B), indicating that TGF-β inhibition compromised the molecular recognition of DNA damage in this population, as well as in GL261 bulk culture.

These data indicate that DNA damage recognition is compromised and that fractionation, which is standard in radiotherapy, would amplify this effect and further compromise DNA repair. To test this hypothesis, we exposed GL261 neurospheres to 3 daily fractions of 2 Gy with or without LY364947 and conducted comet assays to evaluate unresolved DNA damage at 24 h after the final dose (Fig. 5C). Radiation significantly increased the mean tail moment of cells isolated from neurospheres. The mean of those treated with radiation and LY364947 was 19.8 ± 17 SD compared with 6 ± 6 SD for fractionated radiation alone. Less than 5% of non-irradiated cells had tail moments more than 17, compared with 17% for those treated with fractionated radiation and 64% of those from cells treated with the small-molecule TGF-β signaling inhibition and fractionated radiation. These data indicate that TGF-β inhibition not only compromises DNA damage recognition but also prevents DNA repair.

Previously, our studies showed that Tgfb1 null cells fail to mount the full DNA damage response and were radiosensitive (25), as was observed by inhibiting TGF-β signaling in monolayer GBM cultures. Because GIC appeared to be radioresistant, but were sensitized by TGF-β blockade, we hypothesized that increased TGF-β production and/or activity could...
underlie their phenotype. Active and total TGF-β levels in media conditioned for 72 hours from GL261 monolayers or neurospheres were measured using the mink lung epithelial cell luciferase assay. As previously reported, the TGF-β2 isoform accounts for 85% of total TGF-β produced by cells grown under either condition, determined by isoform-specific neutralizing antibodies (data not shown). GL261 cells in neurosphere culture produced significantly more (3.7 ± 1.4-fold, \( P < 0.001 \), ANOVA) total TGF-β and a trend toward more active TGF-β (1.9 ± 1.5-fold, \( P > 0.05 \)) than GL261 cells in monolayer culture (Fig. 5D). Irradiation before treatment with conditioning media under either of the culture conditions did not significantly affect TGF-β levels. Thus, increased production of TGF-β by GL261 neurospheres could be protective as evidenced by a more effective molecular response to radiation-induced DNA damage leading to radiation resistance.

To test the idea that TGF-β inhibition affects GIC self-renewal following IR, we examined CXCR4 and Notch1, which have been implicated in GIC self-renewal pathways (35, 36). Irradiation (2 Gy) of primary neurospheres significantly induced both markers, measured 3 hours following radiation treatment, which was blocked by TGF-β inhibition with LY364947 (Fig. 5E and F). Thus, we concluded that GIC are protected from radiation-induced cell kill by increased TGF-β production under conditions approximating the niche (i.e., neurosphere culture), which promotes effective DNA damage response and self-renewal via CXCR4 and Notch-1. Inhibition of TGF-β signaling compromises both mechanisms.

Discussion

GBM is a cancer characterized by a high degree of radioresistance, evidenced by inevitable local and/or disseminated recurrence. Our study indicates that high TGF-β levels confer resistance for both GIC and more differentiated tumor cells to DNA damage. Tumors have been described as “wounds that do not heal”, whose considerable similarities with the process of wound healing include TGF-β activity. Ionizing radiation is
certainly another source of injury to tumor cells and tumor microenvironment, as well as surrounding normal tissue (20–22, 37). Pharmaceutical TGF-β inhibition circumvents this microenvironment-mediated protection by compromising DNA damage recognition and, therefore, repair, as evidenced by increased clonogenic cell death and unrepairred DNA measured by comet assay. The potential for benefit is likely even higher in situ, as there are multiple sources of TGF-β and multiple modes of action of TGF-β besides the DNA damage response on both cell behavior and tumor microenvironment. Indeed, several studies have shown potential therapeutic benefit for TGF-β inhibition in preclinical glioma models, including antiangiogenesis (38) and anti-invasion (39, 40).

Our previous work showed that genetic depletion of TGF-β1 compromises the DNA damage response in vitro and in vivo (25, 26), and we have now shown in vitro and in vivo radiosensitization with TGF-β inhibitors in breast cancer models (28). The negative impact of TGF-β on response to radiation therapy has been observed in multiple tumor types, further illustrating the well-established pleotropic effects of this cytokine in the tumor microenvironment. The addition of TGF-β inhibitors improves radiation response in preclinical models of GBM (41, 42). Zhang and colleagues specifically reported that the addition of the small-molecule inhibitor of TGF-β receptor type I and II kinase, LY2109761, to the current standard of care treatment, radiation and the oral alkylating agent temozolomide, provided benefit. In addition to radiosensitization and tumor growth delay, TGF-β-signaling blockade had antiangiogenic and antimigration effects as well. Mengxian and colleagues similarly reported radiosensitization, tumor growth delay, and improved survival with the addition of the same small-molecule inhibitor of TGF-β, LY2109761, without combining with temozolomide. They further showed that either TGF-β inhibition or radiation decreased self-renewal of glioma stem-like cells in a neurosphere assay, and a greater decrease was noted when these were combined. Our study provides an explanation of these findings in that autocrine TGF-β potentiates an effective molecular DNA damage response as well as self-renewal.

TGF-β inhibitors are already in phase II/III clinical trials for fibrosis (32, 33). Phase I/II clinical studies using the antisense oligonucleotide AP-12009 (Antisense Pharma, Regensburg, Germany) to target TGF-β2 in recurrent or refractory WHO grade III or IV glioma showed prolonged survival when compared with historical controls (43). More recently, a randomized phase IIb study of AP-12009 in patients with recurrent or refractory GBM or anaplastic astrocytoma showed tumor control rate superiority of lower dose AP-12009 over standard chemotherapy in anaplastic astrocytoma and comparable survival in GBM, with lower rates of toxicity observed with AP-12009 compared with chemotherapy (44).

Our study includes several aspects that add significantly to the growing body of evidence indicating that TGF-β is a therapeutic target in GBM. First, we used both a small-molecule inhibitor of TGF-β type I receptor kinase, LY364947, as well as a pan-specific TGF-β neutralizing antibody, 1D11, to target the TGF-β pathway in combination with IR. Potential advantages seen with clinical use of neutralizing antibodies to TGF-β or its receptor include their longer half-life and potentially more consistent inhibition than small-molecule inhibitors, as well as targeting of all 3 TGF-β isoforms that could be beneficial by affecting not only tumor cells but also the tumor microenvironment. Although the blood–brain barrier does prevent antibody entry into normal brain tissue, the situation is much more complex in the setting of GBM, in which the tumor itself can modulate the blood–brain barrier’s permeability (45). Indeed, the pan-specific TGF-β neutralizing antibody 1D11 has been shown in preclinical orthotopic models to concentrate intratumorally (46). Furthermore, the recent success with bevacizumab (Avastin, an anti-VEGF monoclonal antibody), in both recurrent and newly diagnosed GBM, highlights the feasibility of therapeutic antibodies in CNS tumors (reviewed in ref. 47). Although outcomes have improved, concern over the altered pattern of relapse in patients with bevacizumab-treated GBM, characterized by distant infiltration of the brain by tumors that show increased invasiveness, has emerged (48). Combination therapy with strategies to inhibit invasion have been proposed, and the TGF-β pathway is a logical approach, given the documented role TGF-β plays in glioma migration and invasion (11).

The magnitude of radiosensitization seen in the current study (DER ~1.25 by clonogenic assay) must be taken into context of a disease as difficult to treat as GBM. The DERs currently reported are well within the level of radiosensitization seen in models of glioma. Zheng and colleagues used siRNA silencing of TNF receptor-associated Factor 2 (TRAF2) to radiosensitize U251 glioma cells in vitro with a DER of 1.2 to 1.39 (49). Golding and colleagues reported radiosensitization with DERs of 1.6 to 2.1 in vitro using ATM kinase inhibitors KU-55933 in U87MG glioma cells (50) and KU-60019 in U1242 glioma cells (51). Our study showed that ATM kinase activity is reduced with TGF-β inhibition. More importantly, Kil and colleagues showed a DER of 1.32 using U251 glioma cells treated with temozolomide (52). Considering that the addition of temozolomide to radiation therapy in the treatment of GBM was one of the largest breakthroughs in this disease in decades and is now considered the standard of care, radiosensitization of this magnitude reported here must be considered significant, particularly because the radiation sensitivity of GIC increased nearly 3-fold.

 Debate exists about whether GIC are more (8) or less (53) radioresistant than the tumor cell population as a whole, but it is hypothesized that the GIC population contributes to the inevitable recurrence of GBM (54). Several recent studies have shown that the TGF-β pathway is important in GIC biology (17–19). Although we did not observe inhibition of neurosphere self-renewal with TGF-β inhibition alone (seen in several of the abovementioned studies), we found that TGF-β inhibition in combination with IR prevents self-renewal mediated by CXCR4 and Notch1. These data resolve the paradoxical literature as to GIC radiation sensitivity. We postulate that TGF-β production in the GIC niche is evidence of microenvironment-mediated resistance, and as such represents a very promising target to improve GBM radiotherapy and provide multifaceted benefits that could prevent GBM recurrence.
Disclosure of Potential Conflicts of Interest
S.M. Lonning is employed by Genzyme, Inc. as Senior Director, Oncology Research. No potential conflicts of interest were disclosed by the other authors.

Authors’ Contributions
Conception and design: M.E. Hardee, A.E. Marciscano, D. Zagrag, A. Narayana, S.M. Lonning, M.H. Barcellos-Hoff
Development of methodology: M.E. Hardee, A.E. Marciscano, C.M. Medina-Ramirez
Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): M.E. Hardee, A.E. Marciscano
Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): M.E. Hardee, A.E. Marciscano, C.M. Medina-Ramirez, A. Narayana, M.H. Barcellos-Hoff
Writing, review, and/or revision of the manuscript: M.E. Hardee, A.E. Marciscano, C.M. Medina-Ramirez, D. Zagrag, A. Narayana, S.M. Lonning, M. H, Barcellos-Hoff
Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): M.E. Hardee, A. Narayana

References

Study supervision: M.E. Hardee, A. Narayana, M.H. Barcellos-Hoff
Provided reagents used in experiments: S.M. Lonning

Acknowledgments
ID11 and 13C4 antibodies were provided by Genzyme Inc.

Grant Support
Funding for this study was provided by NYU Department of Radiation Oncology, NCI Integrative Cancer Biology Program, U54-CA149233 and the NCI Training Program in Molecular Oncology and Immunology, 5 T32 CA09161-36 (CMMR).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received February 14, 2012; revised May 17, 2012; accepted May 20, 2012; published OnlineFirst June 12, 2012.
Microenvironment-Mediated Radiation Resistance


Resistance of Glioblastoma-Initiating Cells to Radiation Mediated by the Tumor Microenvironment Can Be Abolished by Inhibiting Transforming Growth Factor-β


Cancer Res  Published OnlineFirst June 12, 2012.

Updated version  Access the most recent version of this article at: doi:10.1158/0008-5472.CAN-12-0546

E-mail alerts  Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions  To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions  To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.